Progressive supranuclear palsy (PSP) is characterized by supranuclear palsy of gaze, axial dystonia, bradykinesia, rigidity, and a progressive dementia. Pathological changes in this disorder are generally restricted to subcortical structures, yet the type and range of cognitive deficits suggest the involvement of many cerebral regions. We examined the extent of functional impairment to cerebral cortical and subcortical structures as measured by the level of glucose metabolic activity at rest. Fourteen patients with PSP were compared to 21 normal volunteers of similar age using "F-2-fluoro-2-deoxy-D-glucose and positron emission tomography. Glucose metabolism was reduced in the caudate nucleus, putamen, thalamus, pons, and cerebral cortex, but not in the cerebellum in the patients with PSP as cornpared to the normal subjects. Analysis of individual brain regions revealed significant declines in cerebral glucose utilization in most regions throughout the cerebral cortex, particularly those in the superior half of the frontal lobe. Declines in the most affected regions of cerebral cortex were greater than those in any single subcortical structure. Although using conventional neuropathological techniques the cerebral cortex appears to be unaffected in PSP, significant and pervasive functional impairments in both cortical and subcortical structures are present. These observations help to account for the constellation of cognitive symptoms in individual patients with PSP and the difficulty encountered in identifying a characteristic psychometric profile for this group of patients. 1988;24:399-406 Progressive supranuclear palsy (PSP) is characterized by supranuclear palsy of gaze, axial dystonia, pseudobulbar palsy with dysarthria and dysphagia, bradykinesia and rigidity, and a progressive dementia 11-51.
Progressive supranuclear palsy (PSP) is characterized by supranuclear palsy of gaze, axial dystonia, pseudobulbar palsy with dysarthria and dysphagia, bradykinesia and rigidity, and a progressive dementia 11-51. Typical pathological features of neuronal loss, distinctive neurofibrillary tangles, and gliosis most conspicuously affect the globus pallidus, subthalamic nucleus, red nucleus, substantia nigra, dentate nucleus, tectum, and periaqueductal gray matter and are limited to subcortical structures; the cerebral cortex generally appears to be unaffected with conventional neuropathological techniques {l, 6}. Despite the apparent lack of cerebral cortical involvement, behavioral changes and dementia are frequent concomitants of this disorder {l, 7, 81. This implies that there may be impairment of cerebral cortical function. Previous studies with '8F-2-fluoro-2-deoxy-D-glucose (I8F-FDG) and positron emission tomography (PET) have demonstrated glucose hypometabolism most prominently in the frontal cortex 19-1 11 . A disturbance in function of the frontal lobes only, however, fails to explain the occurrence in patients with PSP of other symptoms of intellectual decline such as memory impairment, anomia, and visuospatial disturbance, which have classically been localized to other cortical regions. We therefore examined glucose metabolism throughout the cerebral cortex. We also studied metabolic activity in the cerebellum and in subcortical structures that have prominent neuronal loss in this disease, such as the caudate nucleus, putamen, thalamus, and brainstem.
Methods

Patient Selection
Fourteen patients with typical features of PSP (7 men, 7 women, mean age 66 * 6, range 59-75 years) and 21 normal control subjects (13 men, 8 women, mean age 60 * 8, range 46-71 years) were studied. All had cranial computed tomographic (CT) scans showing no localized abnormalities and had not taken any medication with central nervous system effects for at least 2 weeks before the PET study. None had a history of significant head injury or evidence of stroke. The diagnosis of PSP was based on the presence of supranuclear gaze palsy, pseudobulbar palsy, axial and extremity rigidity, and dementia. One patient with this diagnosis has subsequently come to postmortem examination and this revealed multiple system degeneration. Since this patient fulfilled the clinical eligibility criteria for this study his data are included. The normal control subjects were healthy individuals without evidence of neurological or psychiatric illness who had been recruited by advertisement from the community.
PET Method
These studies were approved by the institutional review board and informed consent was obtained from each subject. Subjects were scanned while at rest with eyes patched and ears open to ambient noise in a quiet room. PET images were obtained with a TCC PCT-4600A three-ring, five-slice tomograph (Cyclotron Corporation, Berkeley, CA) following intravenous administration of 5 to 10 mCi of "F-FDG. "E-FDG was synthesized using the reaction of acetyl hypofluorite with triacetylglucal in Freon-1 1 [12] . This method results in less than 5% contamination with 2-deoxy-2-fluoromannose. In each scanning session, a series of four interleaved scans was obtained parallel to the canthomeatal line. This results in up to 20 images with an in-plane resolution of 11 mm full width at half maximum (FWHM) and an axial resolution of 9.5 mm FWHM. Serial arterial blood sam- ples were used to determine IXF-FDG and glucose concentrations. Images were reconstructed following attenuation correction by the standard ellipse method, and local rates of glucose metabolism were calculated using a three-compartment, four-rate constant model with gray matter kineticrate constants derived from normal individuals [ 131.
Image Analysis
Local cerebral metabolic rate for glucose (ICMRGlc) in the cerebral cortex was determined using an automated i m e e analysis program that enhances the contrast in the images, mathematically defines the extent of the gray matter, and then selects a region extending no more than 22 mm inward from the cortical rim, thereby excluding subcortical gray matter. In each patient, 6 horizontal slices extending from the basal ganglia to the top of the centrum semiovale at visually equivalent levels were analyzed. Rates of glucose metabolism were measured in 16 regions of each slice (8 in each hemisphere) representing equal sectors of the cortex (Fig 1) . Mean cerebral cortical metabolism was determined by averaging rates in all regions analyzed. Mean values in each hemisphere were similarly determined. Therefore, hemispheric rates reflect only the contribution of the cerebral cortical gray matter and do not include subcortical structures, white matter, or ventricles. For simplicity of presentation, regional analysis was performed with the means of values obtained from homologous regions of the left and right hemispheres. Values in each brain region for patients with PSP were expressed as a ratio to the mean in that region for normal subjects.
For the analysis of ICMRGlc in the basal ganglia, the image in which the head of the caudate nucleus showed the highest metabolic rates as determined visually from unsmoothed images was selected for measurement of rates in the caudate nucleus and putamen. This same image was generally also used for measurement of metabolic rate of the thalamus. Occasionally, however, the thalamus showed its highest metabolic rates in a slightly more superior image. When this occurred, the second image was used for analyzing thalamic metabolic rates. For each image selected, rates were measured in 7.5 x 11 mm regions centered on (1) the head of the caudate nucleus, approximately one-third of the anterior-posterior extent of the cortex and just posterior to the frontal horns of the lateral ventricles; (2) the putamen, halfway between the caudate cross-section and the anterior extent of the thalamus; and (3) the middle of the thalamus. Positioning of the region was assisted by the use of a histogram showing the rates in successive cross-sections of the image. Mean metabolic rates of the caudate nucleus, putamen, and thalamus consisted of the average of rates determined for the right and left nucleus in each individual.
In the cerebellar hemispheres, vermis, and brainstem ICMRGlc was measured in a region centered over a local peak of activity on the image [ 141. A 22 x 11 mm parallelogram was used for each cerebellar hemisphere, an 11 x 18 mm rectangle for the vermis, and an 11 X 15 mm rectangle was used for the brainstem. Data were obtained from each image (generally 2 or 3) containing the cerebellum and brainstem and represent [he means of values in all images. Data were obtained from the cerebellar vermis by centering the region of interest over the peak activity seen posterior to the brainstem in the midline. The brainstem region chiefly reflects the pons, but the mesencephakm or medulla nblongata could be partially represented.
All estimates of ICMRGlc are expressed as mean 2 standard deviation (SD). Differences between normal and PSP rates were assessed by a two-sample Behrens-Fisher t test (which does not assume equality of variances). The effects of hemisphere, region, and level within a group were tested by a three-way repeated measures analysis of variance (ANOVA).
Results
PET images of glucose metabolic rates obtained from patients with PSP differed noticeably in appearance from those obtained in normal subjects (Fig 2) . Regional analysis demonstrated that patients with PSP had lower glucose metabolic rates in the cerebral cortex, caudate nucleus, putamen, thalamus, and brainstem (Table 1 , Figs 3-5). There was also a tendency for cerebellar hemispheric rates t o be lower in those with PSP than in the normal subjects, but rates in the cerebellar vermis were unchanged. Significant declines in lCMRGlc were present throughout the cerebral cortex. Anterior brain regions, particularly those in the superior half of the cortex, were most impaired (Fig 6) . ANOVA of both level (p < 0.0001) and region (p < 0.0001) in the patients with PSP. This effect was larger for region than for level. Relative to the rates seen in normal subjects, the declines were greatest in the superioranterior frontal regions, followed by the caudate nucleus, putamen, thalamus, brainstem, and most other areas of the cerebral cortex (see Table 1 , Fig 6) . Cerebellar hemispheres and vermis were least affected.
No significant asymmetries were observed in t6e lCMRGlc for the caudate nucleus, putamen, or thalamus in either patients or normal subjects; however, the cerebral cortex, which was symmetrical in normal subjects, was decreased in the left hemisphere (as compared to the right) in patients with PSP. Significant asymmetry of cerebellar hemisphere metabolism was observed in normal subjects, but not in patients with PSP (Table 2) . It was not possible to match our patient group to our cohort of aged normal subjects for both age and sex because the normal subjects are used for many different studies at our center. Consequently, the effects of age and sex were investigated in both the normal subjects and patients. There was no correlation of age with lCMRGlc, and no significant differences in ICMRGlc were observed between the sexes in either the patient or control groups.
Discussion
The present study demonstrates that neuronal function as measured by regional glucose metabolism is impaired not only in the frontal region of the cerebral cortex as described previously {9}, but also in the remainder of the cerebral cortex as well as in the brainstem, basal ganglia, and thalamus in patients with PSP as compared to normal subjects of similar age. Cere--bellar neuronal function shows little change, but the resolution of our PET scanner is not sufficient to discriminate the metabolic activity of the dentate nucleus, where substantial abnormality has been describe4 [ By light microscopy, the loss of neurons in PSI' is most severe in the midbrain tecturn, including the superior colliculi, substantia nigra, basal pontine nuclei, and periaqueductal gray matter. Less severe neuronal loss is also seen in the rcd nucleus and locus ceruleus { I , 3, IS]. In some patients, motor cranial nuclei { 18, 191 are also affected. The resolution of the PET scanner used in our studies is insufficient to discriminate these structures individually; however, neuronal loss is still the most likely explanation for the decline of ICMRGlc observed in the brainstem.
The globus pallidus, subthalamic nucleus, and me.-dial periventricular portions of the thalamus :show formed, however, loss of some neurons cannot be excluded. Many afferent projections to the cerebral cortex are damaged, and this may account for the changes in ICMRGlc observed in this study. The nucleus basalis of Meynert, which suffers significant neuronal loss in PSP [24] , projects diffusely to the cerebral cortex. A decline in cerebral cortical choline acetyltransferase in PSP is attributable to degeneration of projections from this structure 120). The locus ceruleus, as mentioned above, shows significant neuronal loss and also projects diffusely to the cerebral cortex. The asymmetry of hypometabolism in the cortex suggests that subcortical structures may also be asymmetrically involved, at least in earlier stages of the illness. Although a decrease in ICMRGlc in the cerebral cortex generally may result from deafferentation, the prominence of frontal lobe hypometabolism is more difficult to explain. The thalamus, nucleus basalis of Mrynert, globus pallidus, and other subcortical structures project soniatotopically to the cortex, and conceivably, localized damage to one or more of these structures could account for the pattern of frontal hypometabolism that we observed. Until more is known about the distribution of neuronal loss in subcortical structures that project to the frontal lobe, it is difficult to know whether deafferentation is sufficient to explain the pattern of hypometabolism observed in the cerebral cortex. Some symptoms of PSP can be predicted on the basis of neuropathological observations. Prominent extrapyramidal signs that in some cases lead to a misdiagnosis of Parkinson's disease [ S ] result from functional impairment of the basal ganglia. Dysphagia, dysarthria, and some of the disturbance of ocular motility are likely the result of damage to brainstem nuclei and tracts. Ataxia is due to damage of cerebellar efferent pathways. Other symptoms, however, cannot be adequately explained by postmortem studies, and PET provides a better understanding of their pathogenesis.
Patients with PSP exhibit a variety of behavioral and intellectual changes that classically have been localized to the cerebral cortex. Apathy or depression, memory loss, dysphasia, impaired judgment, and perseveration all may be observed in patients with this disease [7, 8, [25] [26] [27] . The concept of subcortical dementia was developed to account for these changes in the absence of clear neuropathological change in the cerebral cortex 177; however, recently the distinction between subcortical and cortical dementias has become blurred 1281.
FDG-PET now provides evidence that in PSP there is functional impairment in the cerebral cortex and that this may account for some of the intellectual and behavioral changes observed in these patitints. Glucose hypometabolism is most prominent in the frontal lobe, and many symptoms attributable to frontal lobe dysfunction are seen in patients with PSP {S, 9, 271. ily, although they can do so refkxively [ 331. I-hlethyl-4-phenyl-l,2,3,6-tetrahydropyric~ine (MPTP)-induced parkinsonism in monkeys has been found to Jecrease glucose metabolism in the paralamellar rnctiiodc rsal thalamus and in the frontal eye tields. These Jeclines are reversed by the administration of levodopa, which suggests that they may be dopaminergic in origin {, 14] . In these monkeys, oculomotor abnormalities were also reversed by levodopa. Levodopa therapy ctoes i i o t usually improve eye movements in patients with PSP, and thus it is not clear whether a similar mechaiiism can account for our findings.
Declines in the metabolism of the frontal cortex arc the most apparent changes observed when FDG.-PET is used in patients with PSP. This pattern is quite distinctive from that seen in Alzheimer's discxse where more posterior regions of the cerebral cortex are mmi: impaired, and the frontal cortex is relatively spareJ 1 101. Hypometabolism, most prominent in the frontal cortex, has also been observed in Parkinson's disease uncomplicated by dementia 13 5 } and Pick's disease 136, 377; however, no declines of glucose metabolism in brainstem, basal ganglia, or thalamus were observed in these disorders. FDG-PET is helpful in differentiating PSP from other diseases leading to gait instability such as olivopontocerebellar atrophy (OPCA). Distinguishing these two diseases can be difficult, particularly in the early stages of the illness and in view of the observation of supranuclear gaze palsy in some patients with OPCA C38). Patients with OPCA show hypometabolism in the cerebellar hemispheres and vermis and in the brainstem but have normal values in the thalamus and cerebral cortex [14, 391, a pattern quite distinct from that observed in patients with PSP.
In the present study, rate constants derived from normal subjects have been used in computing 1CMRGlc. The applicability of these rate constants in disease states such as PSP has not yet been tested. We have made no corrections for atrophy, although atrophy of the pontine tegmentum is often apparent at gross examination of the brain after death 13, 151 and has been noted using high-resolution CT 140-421. the measurement of subcortical structures. We have chosen a method that centers a uniform region of interest over the peak activity corresponding to a subcortical structure, rather than attempting to outline the entire extent of the structure based on its anatomy or appearance on the image. This should minimize the error due to difficulties in visualizing a hypometabolic structure. The significance of atrophy in our studies, however, is not known. Even if problems with rate constants and partial volume effects are found to make a difference in the interpretation of the present results, these factors do not negate the diagnostic utility of our observations.
Patients with PSP demonstrate a distinctive pattern of glucose hypometabolism that accounts for many of the characteristic features of this disease. The extent to which this pattern results from intrinsic neuronal damage or deafferentation cannot at present be determined; however, FDG-PET contributes to our understanding of this disease and in the future may play an important role in improving the accuracy of clinical diagnosis.
